Form 4: DBV Technologies CMO Sells Shares to Cover Tax Obligations

DBV Technologies' Chief Medical Officer, Pharis Mohideen, sold 397 ordinary shares to cover tax obligations related to restricted stock unit vesting.

Summary

• Pharis Mohideen, Chief Medical Officer of DBV Technologies S.A. (DBVT), reported a transaction involving the sale of company shares.
• On May 22, 2025, Mr. Mohideen disposed of 397 ordinary shares.
• The shares were sold at a price of $1.84 per share.
• The sale was conducted to satisfy withholding tax obligations upon the vesting of restricted stock units.
• Following this transaction, Mr. Mohideen beneficially owns 110,113 ordinary shares directly.
• The ordinary shares may be represented by American Depositary Shares (ADS), with each ADS currently representing one ordinary share.
• The sales price of $1.84 per share is in US Dollars, reflecting a conversion from EURO at an exchange rate of $1.1303 to EURO 1.00 as of May 22, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine, non-discretionary sale for tax purposes, not indicative of management's view on the company's future performance.

Negatives

• The transaction represents a reduction in insider ownership, though it is a non-discretionary sale for tax purposes.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The sale of 397 ordinary shares was made to satisfy withholding tax obligations upon the vesting of restricted stock units.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically a non-discretionary sale to cover tax liabilities on vested equity. It does not provide insights into broader industry trends or competitive positioning within the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: A very minor reduction in insider ownership, unlikely to have a significant impact given the small number of shares and the non-discretionary nature of the sale.
• Employees: The transaction relates to equity compensation, which is a common component of executive remuneration.

Key Dates

Keywords

DBV Technologies, DBVT, Form 4, Insider Transaction, Stock Sale, Chief Medical Officer, Restricted Stock Units, Tax Obligations, Equity Compensation